TrueTicker

NIFTY 500 › Chemicals

Chemicals · NIFTY 500

Privi Speciality Chemicals Ltd.

PRIVISCL on NSE · 19 Nov 2026

NIFTY 500

3,535.00 ▲ +2.81 % on the day

Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance

Guidance tracker

What PRIVISCL guided, and what came next

FiledWhat the filing saysNext results: profit YoYRevenueMove on the day
03 Nov 2026Transcript of the Q2 and H1 FY27 earnings conference call held October 30, 2026 on Privi Speciality Chemicals' unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Management said Q2 total income was INR773.16 crores (up 13.9% YoY), EBITDA INR212.49 crores (up... NSE copy No results filed since
30 Oct 2026Privi Speciality Chemicals filed its investor presentation on Q2 and H1 FY27 (quarter and half year ended September 30, 2026) with the stock exchanges. Q2 FY27 consolidated total income Rs 773.16 Cr (up 13.9% YoY), EBITDA Rs 212.49 Cr (up 16.7% YoY, margin 27.48%), and PAT attributable to the company Rs 117.03 Cr... NSE copy No results filed since
03 Aug 2026Privi Speciality Chemicals filed the transcript of its Q1 FY27 analyst/investors call held on July 30-31, 2026, on the quarter ended June 30, 2026. Management said consolidated total income was about Rs. 681.42 crore (up 20.01% YoY), EBITDA Rs. 167.47 crore (up 18.73% YoY) at about 24.58% margin, and PAT about Rs.... NSE copy +29.7 %+12.0 %-2.4 %
30 Jul 2026Privi Speciality Chemicals filed its investor presentation on financial and operational review for the quarter ended June 30, 2026 (Q1 FY27), ahead of an earnings call on July 31, 2026. Management reported total income of Rs 681.42 Cr, up 20.01% year-on-year, and EBITDA of Rs 167.47 Cr, up 18.73% year-on-year, with... NSE copy +29.7 %+12.0 %-2.4 %
15 May 2026Privi Speciality Chemicals filed the transcript of its Q4 and FY26 earnings call held on May 12, 2026. Management (Chairman Mahesh Babani, CFO Narayan S. Iyer) reported Q4 FY26 total income of INR725.70 crore (up 15.29% YoY), EBITDA of INR184.41 crore (up 25.09%), EBITDA margin of 25.41% and PAT of INR95.66 crore... NSE copy +36.0 %+19.2 %+1.2 %
16 Feb 2026Transcript of the Q3 and 9M FY26 earnings conference call of Privi Speciality Chemicals held on February 10, 2026, filed with BSE and NSE. Management said Q3 total income was INR611.15 crores, up 25% year-on-year, with EBITDA of INR158 crores (25.83% margin), up 37%; PAT adjusted for a one-time Labour Code impact... NSE copy ---0.4 %
10 Feb 2026Privi Speciality Chemicals filed its investor presentation on financial and operational review for the quarter and nine months ended December 31, 2025, following an earnings call on February 10, 2026. Consolidated Q3 FY26 revenue from operations was Rs. 604.64 crore (Rs. 490.87 crore in Q3 FY25); total income was... NSE copy ---0.4 %
14 Nov 2025Privi Speciality Chemicals filed the transcript of its Q2 and H1 FY'26 earnings conference call held on November 7, 2025, covering results for the quarter and half year ended September 30, 2025. Management (CFO Narayan S. Iyer) said Q2 consolidated total income was Rs. 678.82 crores, up 26% year-on-year, with... NSE copy +75.5 %+23.2 %-0.5 %
06 Nov 2025Privi Speciality Chemicals filed its investor presentation on financial and operational review for the quarter and half year ended September 30, 2025, with an earnings call scheduled for November 7, 2025 at 4:00 pm IST. Consolidated revenue for Q2FY26 was Rs. 678.82 crore, up 26% YoY; EBITDA was Rs. 182.14 crore,... NSE copy +75.5 %+23.2 %-0.5 %
11 Aug 2025Privi Speciality Chemicals filed the transcript of its Q1 FY'26 earnings call held on August 05, 2025, on the quarter ended June 30, 2025. Management (Narayan S. Iyer, CFO) said consolidated income was about Rs. 568 crores, up about 22% year-on-year; consolidated EBITDA was about Rs. 141 crores (45% growth) at a... NSE copy +102.0 %+27.4 %+9.9 %
05 Aug 2025Privi Speciality Chemicals filed its investor presentation on financial and operational review for the quarter ended June 30, 2025 (Q1 FY25-26), with an earnings call held on August 5, 2025 at 4:00 pm IST. Standalone revenue from operations rose 29.6% to Rs 574.7 Cr and consolidated revenue rose 21.7% to Rs 567.8... NSE copy +102.0 %+27.4 %+9.9 %
12 May 2025Privi Speciality Chemicals filed the transcript of its analyst/investor call held on May 6, 2025, on the audited standalone and consolidated results for Q4 and FY25 (quarter and year ended March 31, 2025). Management said Q4 FY25 total income was a record Rs.628 crores (up 28% YoY), EBITDA Rs.147 crores (up 50%... NSE copy -+20.4 %-4.0 %
05 May 2025Privi Speciality Chemicals filed its investor presentation on Q4 and FY25 financial and operational review, following an earnings call on May 6, 2025. Management said Q4 FY25 was the highest-ever quarterly performance: consolidated total income Rs 628.37 crores (up 28% YoY), EBITDA Rs 147.42 crores (up 50%), PAT Rs... NSE copy -+20.4 %-4.0 %
18 Feb 2025Privi Specialty Chemicals filed the transcript of its Q3 FY25 earnings conference call held on February 13, 2025, covering results for the quarter ended December 31, 2024. Management said Q3 total income was about INR493 crores with EBITDA of about INR115 crores (margin about 23%) and profit after tax of about... NSE copy -+20.4 %-4.0 %

Filings tagged as guidance, newest first (14 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.

Governance

Management, auditors, ratings and legal matters

FiledKindWhat the filing says
30 Jun 2026Credit ratingPrivi Speciality Chemicals Limited filed intimation under Regulation 30(6) of the SEBI LODR Regulations, 2015, reporting credit ratings. ICRA Limited assigned a long-term rating of AA with Stable outlook. The rated facility is a long-term fund-based term loan of Rs. 300 crores availed from ICICI Bank Limited.... NSE copy
30 Jun 2026Credit ratingPrivi Speciality Chemicals Limited filed intimation under Regulation 30(6) of SEBI LODR regarding credit ratings. ICRA Limited has assigned a long-term rating of AA, Outlook: Stable, to the Rs. 300 crore long-term fund-based term loan availed from ICICI Bank Limited. The rating action is shown as "Assigned"; the... NSE copy
11 May 2026Management changeBoard of Privi Speciality Chemicals Limited approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, at a meeting held May 11, 2026. Board recommended a final dividend of Rs. 10 per equity share of Rs. 10 each (100%) for FY 2025-26, subject to shareholder... NSE copy
11 May 2026Management changeBoard meeting held on May 11, 2026 approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with the statutory auditor's report enclosed. Board recommended a final dividend of Rs. 10/- (100%) per equity share of Rs. 10/- each for FY 2025-26, subject to... NSE copy
06 May 2026Legal or regulatoryPrivi Speciality Chemicals Limited filed an intimation under SEBI LODR Regulation 30 on receipt of an observation letter with 'no objection' from BSE Limited, dated May 06, 2026, on the proposed scheme of amalgamation. The scheme merges Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited... NSE copy
06 May 2026Legal or regulatoryPrivi Speciality Chemicals Limited intimated that it has received an observation letter with "no objection" from the National Stock Exchange of India Limited, dated May 2026 (day garbled in OCR), on the proposed scheme of amalgamation with Privi Fine Sciences Private Limited and Privi Biotechnologies Private... NSE copy
21 Apr 2026Credit ratingPrivi Speciality Chemicals Limited filed intimation under Regulation 30(6) of SEBI LODR on the rating action by CRISIL Ratings Limited. CRISIL reaffirmed the long-term rating at AA-/Stable on the bank facilities. CRISIL reaffirmed the short-term rating at A1+ on the bank facilities. Total bank loan facilities rated... NSE copy
19 Dec 2025Legal or regulatoryThe board of Privi Speciality Chemicals Limited, at its meeting held on December 19, 2025, approved a Scheme of Amalgamation under Sections 230 to 232 of the Companies Act, 2013. The scheme provides for amalgamation of Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited (a wholly owned... NSE copy
19 Dec 2025Legal or regulatoryThe Board of Privi Speciality Chemicals Limited, at its meeting held on December 19, 2025 (3:00 p.m. to 5:00 p.m.), approved a Scheme of Amalgamation under Sections 230 to 232 of the Companies Act, 2013. The scheme provides for amalgamation of Privi Fine Sciences Private Limited and Privi Biotechnologies Private... NSE copy
15 Nov 2025Legal or regulatoryPrivi Speciality Chemicals Limited filed the outcome of its board meeting held on November 15, 2025 (11:00 a.m. to 11:45 a.m.). The board approved withdrawal of the Scheme of Amalgamation of Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited with the company and their shareholders, filed... NSE copy
14 Jun 2025Legal or regulatoryPrivi Speciality Chemicals Limited filed the outcome of its board meeting held on June 14, 2025 (meeting ran from 11:30 a.m. to 12:50 p.m.). The board decided not to proceed with a qualified institutions placement of equity shares aggregating up to Rs 1,000 crores, citing improved performance and sufficient cash... NSE copy
14 Jun 2025Legal or regulatoryBoard of Privi Speciality Chemicals Limited met on June 14, 2025 (11:30 a.m. to 12:50 p.m.) and decided not to proceed with the qualified institutions placement of equity shares aggregating up to Rs 1,000 crores, citing improved performance and sufficient cash accruals for capex. The Board approved a scheme of... NSE copy
03 May 2025Management changePrivi Speciality Chemicals Limited filed the outcome of its board meeting held on May 3, 2025, approving audited standalone and consolidated financial results for the quarter and year ended March 31, 2025. The board recommended a final dividend of Rs. 5/- (50%) per equity share of Rs. 10/- each for FY2024-25,... NSE copy
10 Mar 2025Credit ratingPrivi Speciality Chemicals Limited filed intimation under SEBI LODR Regulation 30(6) of a rating revision by CRISIL Ratings Limited, dated March 10, 2025. Long-term rating upgraded from Crisil A+/Positive to Crisil AA-/Stable; short-term rating upgraded from Crisil A1 to Crisil A1+. Total bank loan facilities rated... NSE copy
12 Feb 2025Management changeBoard meeting held on February 12, 2025 (12:00 noon to 3:10 p.m.) approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, with statutory auditors' limited review report (BSR&Co. LLP), enclosed as Annexure A. Dwarko Topandas Khilnani (DIN:... NSE copy
12 Feb 2025Management changeBoard of Privi Speciality Chemicals Limited approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, with limited review reports from statutory auditors (Annexure A). Independent Non-Executive Director Dwarko Topandas Khilnani (DIN: 01824655)... NSE copy
12 Feb 2025Management changeBoard of Privi Speciality Chemicals Limited met on February 12, 2025 (12:00 noon to 3:10 p.m.) and approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, with the statutory auditor's limited review report (Annexure A). Mr. Dwarko Topandas Khilnani... NSE copy
29 Nov 2024Management changeBoard of Privi Speciality Chemicals Limited approved the "Privi Employee Stock Option Scheme 2024" (Privi ESOS 2024) at a meeting held on November 29, 2024 (4:00 p.m. to 5:00 p.m.), on NRC recommendation. The scheme permits grant of options not exceeding 2% of paid-up equity share capital, i.e. 7,81,250 equity... NSE copy

Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (18 in all). A list of what was filed, not a judgement of the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in